Literature DB >> 19457988

Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Maria Carmen Puertas1, Maria Jose Buzón, Anna Artese, Stefano Alcaro, Luis Menendez-Arias, Carlo Federico Perno, Bonaventura Clotet, Francesca Ceccherini-Silberstein, Javier Martinez-Picado.   

Abstract

A negative association between polymorphism Leu-214 and type-1 thymidine analogue mutations (TAM1) and a positive association with a clinically favorable virological response to thymidine analogue-based combination antiretroviral therapy have been described. In this study, the impact of Leu-214 on replication capacity and resistance to zidovudine (ZDV) of viruses containing TAM1 or TAM2 was determined. Leu-214 decreased the growth rate of viruses bearing Tyr-215, as well as their resistance to ZDV. This observation was confirmed by structural and molecular modeling data, suggesting a regulatory role for Leu-214 in the emergence and phenotypic resistance of TAM1.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19457988      PMCID： PMC2708641          DOI： 10.1128/JVI.00487-09

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.

Authors:  Mina John; Corey B Moore; Ian R James; Simon A Mallal
Journal:  Antivir Ther       Date:  2005

2.  Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Authors:  P R Harrigan; S Bloor; B A Larder
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions.

Authors:  A C Wallace; R A Laskowski; J M Thornton
Journal:  Protein Eng       Date:  1995-02

4.  High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.

Authors:  Francesca Ceccherini-Silberstein; Federico Gago; Maria Santoro; Caterina Gori; Valentina Svicher; Fátima Rodríguez-Barrios; Roberta d'Arrigo; Massimo Ciccozzi; Ada Bertoli; Antonella d'Arminio Monforte; Jan Balzarini; Andrea Antinori; Carlo-Federico Perno
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Authors:  Javier Martinez-Picado; Terri Wrin; Simon D W Frost; Bonaventura Clotet; Lidia Ruiz; Andrew J Leigh Brown; Christos J Petropoulos; Neil T Parkin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.

Authors:  Alessandro Cozzi-Lepri; Lidia Ruiz; Clive Loveday; Andrew N Phillips; Bonaventura Clotet; Peter Reiss; Bruno Ledergerber; Christian Holkmann; Schlomo Staszewski; Jens D Lundgren
Journal:  Antivir Ther       Date:  2005

8.  Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.

Authors:  Andrea De Luca; Simona Di Giambenedetto; Laura Romano; Angela Gonnelli; Paola Corsi; Marco Baldari; Massimo Di Pietro; Stefano Menzo; Daniela Francisci; Paolo Almi; Maurizio Zazzi
Journal:  J Infect Dis       Date:  2006-03-28       Impact factor: 5.226

9.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.

Authors:  P R Meyer; S E Matsuura; A G So; W A Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Authors:  A J Japour; S Welles; R T D'Aquila; V A Johnson; D D Richman; R W Coombs; P S Reichelderfer; J O Kahn; C S Crumpacker; D R Kuritzkes
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226
View more
  7 in total

1.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

2.  Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

3.  HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Paul L Boyer; Patrick K Clark; Stephen H Hughes
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

4.  Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.

Authors:  Gilberto Betancor; Maria C Puertas; María Nevot; César Garriga; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

5.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

6.  Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C.

Authors:  Rodrigo D Cunha; Celina M Abreu; Luis M F Gonzalez; Monique Nijhuis; Dorien de Jong; Renato S Aguiar; Adriana O Afonso; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

7.  Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Authors:  Gilberto Betancor; César Garriga; Maria C Puertas; María Nevot; Lourdes Anta; José L Blanco; M Jesús Pérez-Elías; Carmen de Mendoza; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias; José Antonio Iribarren; Estrella Caballero; Esteban Ribera; Josep Maria Llibre; Bonaventura Clotet; Angels Jaén; David Dalmau; José María Gatel; Joaquín Peraire; Francesc Vidal; Carmen Vidal; Melchor Riera; Juan Córdoba; José López Aldeguer; María José Galindo; Félix Gutiérrez; Marta Álvarez; Federico García; Pilar Pérez-Romero; Pompeyo Viciana; Manuel Leal; José Carlos Palomares; Juan Antonio Pineda; Isabel Viciana; Jesús Santos; Patricia Rodríguez; Juan Luis Gómez Sirvent; Carolina Gutiérrez; Santiago Moreno; Mayte Pérez-Olmeda; José Alcamí; Carmen Rodríguez; Jorge del Romero; Angelina Cañizares; José Pedreira; Celia Miralles; Antonio Ocampo; Luis Morano; Antonio Aguilera; Carolina Garrido; Gustavo Manuzza; Eva Poveda; Vicente Soriano
Journal:  Retrovirology       Date:  2012-08-13       Impact factor: 4.602
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.